Abvc Biopharma (ABVC) EBT (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly EBT came in at -$1.7 million in Q1 2026, down 78.98% YoY from -$8.0 million in Q1 2025, and up 43.98% on a QoQ basis from -$3.0 million in Q4 2025.
Abvc Biopharma (ABVC) EBT (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 16 years of EBT data on file, last reported at -$1.7 million in Q1 2026.
- Quarterly EBT fell 78.98% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.1 million (down 168.7% YoY) and the FY2025 annual result came in at -$8.4 million, down 55.56% from the prior year.
- EBT improved to -$1.7 million in Q1 2026, from -$3.0 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$487076.0 in Q3 2024 to a low of -$6.2 million in Q1 2022.
- A 5-year average of -$2.3 million and a median of -$2.1 million in 2025 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT tumbled 395.41% — and 2024, when it soared 85.54%.
- Tracing ABVC's EBT over 5 years: stood at -$3.5 million in 2022, then soared by 85.16% to -$524999.0 in 2023, then slumped by 51.72% to -$796527.0 in 2024, then plunged by 278.7% to -$3.0 million in 2025, then jumped by 43.98% to -$1.7 million in 2026.
- The last three EBT figures came in at -$1.7 million (Q1 2026), -$3.0 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Abvc Biopharma | 23.34 Mn | 23.34 Mn | - | -810,481.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -810,481.00 |
| Mar 31, 2026 | -1.69 Mn |
| Dec 31, 2025 | -3.02 Mn |
| Sep 30, 2025 | -2.08 Mn |
| Jun 30, 2025 | -2.31 Mn |
| Mar 31, 2025 | -944,190.00 |
| Dec 31, 2024 | -796,527.00 |
| Sep 30, 2024 | -487,076.00 |
| Jun 30, 2024 | -1.16 Mn |
| Mar 31, 2024 | -2.93 Mn |
| Dec 31, 2023 | -524,999.00 |
| Sep 30, 2023 | -3.37 Mn |
| Jun 30, 2023 | -2.23 Mn |
| Mar 31, 2023 | -1.90 Mn |
| Dec 31, 2022 | -3.54 Mn |
| Sep 30, 2022 | -3.77 Mn |
| Jun 30, 2022 | -2.03 Mn |
| Mar 31, 2022 | -6.17 Mn |
| Dec 31, 2021 | -5.89 Mn |
| Sep 30, 2021 | -1.96 Mn |